{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T18:29:03Z","timestamp":1778178543866,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004077","name":"Kocaeli \u00dcniversitesi","doi-asserted-by":"publisher","award":["Grant number 2015\/035"],"award-info":[{"award-number":["Grant number 2015\/035"]}],"id":[{"id":"10.13039\/501100004077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11255-018-1914-x","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T02:54:51Z","timestamp":1529549691000},"page":"1417-1425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Histopathologic and molecular comparative analyses of intravesical Aurora kinase-A inhibitor Alisertib with bacillus Calmette\u2013Gu\u00e9rin on precancerous lesions of bladder in a rat model"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9030-4662","authenticated-orcid":false,"given":"Kerem","family":"Teke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Kemal","family":"Uslubas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurler","family":"Akpinar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Kasap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oguz","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demir Kursat","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nil","family":"Guzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozdal","family":"Dillioglugil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"1914_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21332","journal-title":"CA Cancer J Clin"},{"key":"1914_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234\u2013241. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033","journal-title":"Eur Urol"},{"key":"1914_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1517\/14656561003657145","volume":"11","author":"SK Williams","year":"2010","unstructured":"Williams SK, Hoenig DM, Ghavamian R, Soloway M (2010) Intravesical therapy for bladder cancer. Expert Opin Pharmacother 11:947\u2013958. \n                    https:\/\/doi.org\/10.1517\/14656561003657145","journal-title":"Expert Opin Pharmacother"},{"issue":"6 Suppl 4","key":"1914_CR4","first-page":"S199-205","volume":"3","author":"AR Zlotta","year":"2009","unstructured":"Zlotta AR, Fleshner NE, Jewett MA (2009) The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 3(6 Suppl 4):S199-205","journal-title":"Can Urol Assoc J"},{"key":"1914_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.juro.2014.08.106","volume":"193","author":"KL Ferrari","year":"2015","unstructured":"Ferrari KL, de Camargo JA, Rocha GZ, Carvalheira JB, Saad MJ, Billis A, Reis LO (2015) Intravesical bacillus Calmette-Guerin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer. J Urol 193:682\u2013689. \n                    https:\/\/doi.org\/10.1016\/j.juro.2014.08.106","journal-title":"J Urol"},{"key":"1914_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.juro.2011.10.022","volume":"187","author":"LO Reis","year":"2012","unstructured":"Reis LO, Ferreira U, Billis A, Cagnon VH, Favaro WJ (2012) Anti-angiogenic effects of the superantigen staphylococcal enterotoxin B and bacillus Calmette-Guerin immunotherapy for nonmuscle invasive bladder cancer. J Urol 187:438\u2013445. \n                    https:\/\/doi.org\/10.1016\/j.juro.2011.10.022","journal-title":"J Urol"},{"key":"1914_CR7","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1517\/14728222.2014.956085","volume":"18","author":"M Malumbres","year":"2014","unstructured":"Malumbres M, Perez de Castro I (2014) Aurora kinase A inhibitors: promising agents in antitumoral therapy. Expert Opin Ther Targets 18:1377\u20131393. \n                    https:\/\/doi.org\/10.1517\/14728222.2014.956085","journal-title":"Expert Opin Ther Targets"},{"key":"1914_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00345-014-1267-8","volume":"33","author":"M Martino de","year":"2015","unstructured":"de Martino M, Shariat SF, Hofbauer SL, Lucca I, Taus C, Wiener HG, Haitel A, Susani M, Klatte T (2015) Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. World J Urol 33:105\u2013110. \n                    https:\/\/doi.org\/10.1007\/s00345-014-1267-8","journal-title":"World J Urol"},{"key":"1914_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1158\/1535-7163.MCT-09-0765","volume":"9","author":"AA Dar","year":"2010","unstructured":"Dar AA, Goff LW, Majid S, Berlin J, El-Rifai W (2010) Aurora kinase inhibitors\u2013rising stars in cancer therapeutics? Mol Cancer Ther 9:268\u2013278. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0765","journal-title":"Mol Cancer Ther"},{"key":"1914_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0009-2797(72)90040-3","volume":"5","author":"RM Hicks","year":"1972","unstructured":"Hicks RM, Wakefield JS (1972) Rapid induction of bladder cancer in rats with N-methyl-N-nitrosourea. I. Histology. Chem Biol Interact 5:139\u2013152","journal-title":"Chem Biol Interact"},{"key":"1914_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1538\/expanim.16-0093","volume":"66","author":"K Teke","year":"2017","unstructured":"Teke K, Ozkan TA, Cebeci OO, Yilmaz H, Keles ME, Ozkan L, Dillioglugil MO, Yildiz DK, Dillioglugil O (2017) Preventive effect of intravesical ozone supplementation on N-methyl-N-nitrosourea-induced non-muscle invasive bladder cancer in male rats. Exp Anim 66:191\u2013198. \n                    https:\/\/doi.org\/10.1538\/expanim.16-0093","journal-title":"Exp Anim"},{"key":"1914_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00262-017-2063-2","volume":"67","author":"K Teke","year":"2018","unstructured":"Teke K, Guzel N, Uslubas AK, Kasap M, Yilmaz H, Akpinar G, Yildiz DK, Dillioglugil O (2018) Monitoring the response of urothelial precancerous lesions to bacillus Calmette-Guerin at the proteome level in an in vivo rat model. Cancer Immunol Immunother 67:67\u201377. \n                    https:\/\/doi.org\/10.1007\/s00262-017-2063-2","journal-title":"Cancer Immunol Immunother"},{"key":"1914_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/1535-7163.MCT-10-0577","volume":"10","author":"J Zeng","year":"2011","unstructured":"Zeng J, Sun Y, Wu K, Li L, Zhang G, Yang Z, Wang Z, Zhang D, Xue Y, Chen Y, Zhu G, Wang X, He D (2011) Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Mol Cancer Ther 10:104\u2013116. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0577","journal-title":"Mol Cancer Ther"},{"key":"1914_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1158\/1078-0432.CCR-12-2383","volume":"19","author":"N Zhou","year":"2013","unstructured":"Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R, Ecsedy JA, Zhang Z, Teh BT, Almasan A, Hansel DE (2013) The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res 19:1717\u20131728. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2383","journal-title":"Clin Cancer Res"},{"key":"1914_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/106689690501300203","volume":"13","author":"R Montironi","year":"2005","unstructured":"Montironi R, Lopez-Beltran A (2005) The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 13:143\u2013153","journal-title":"Int J Surg Pathol"},{"key":"1914_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5152\/tud.2017.60376","volume":"43","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Bagcioglu M, Huri E (2017) What is new in non-muscle-invasive bladder cancer in 2016? Turk J Urol 43:9\u201313. \n                    https:\/\/doi.org\/10.5152\/tud.2017.60376","journal-title":"Turk J Urol"},{"key":"1914_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1479-5876-8-122","volume":"8","author":"S Blanco","year":"2010","unstructured":"Blanco S, Raber M, Leone BE, Nespoli L, Grasso M (2010) Early detection of urothelial premalignant lesions using hexaminolevulinate fluorescence cystoscopy in high risk patients. J Transl Med 8:122. \n                    https:\/\/doi.org\/10.1186\/1479-5876-8-122","journal-title":"J Transl Med"},{"key":"1914_CR18","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22:1435\u20131448","journal-title":"Am J Surg Pathol"},{"key":"1914_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014Part B: prostate and bladder tumours. Eur Urol 70:106\u2013119. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.02.028","journal-title":"Eur Urol"},{"key":"1914_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/01.MP.0000056628.38714.5D","volume":"16","author":"C Mallofre","year":"2003","unstructured":"Mallofre C, Castillo M, Morente V, Sole M (2003) Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol 16:187\u2013191. \n                    https:\/\/doi.org\/10.1097\/01.MP.0000056628.38714.5D","journal-title":"Mod Pathol"},{"key":"1914_CR21","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.urology.2007.12.026","volume":"72","author":"E Comperat","year":"2008","unstructured":"Comperat E, Bieche I, Dargere D, Laurendeau I, Vieillefond A, Benoit G, Vidaud M, Camparo P, Capron F, Verret C, Cussenot O, Bedossa P, Paradis V (2008) Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. Urology 72:873\u2013877. \n                    https:\/\/doi.org\/10.1016\/j.urology.2007.12.026","journal-title":"Urology"},{"key":"1914_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2490-5-8","volume":"5","author":"F Chen","year":"2005","unstructured":"Chen F, Zhang G, Iwamoto Y, See WA (2005) BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. BMC Urol 5:8. \n                    https:\/\/doi.org\/10.1186\/1471-2490-5-8","journal-title":"BMC Urol"},{"key":"1914_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/bjo.82.8.961","volume":"82","author":"SE Coupland","year":"1998","unstructured":"Coupland SE, Bechrakis N, Schuler A, Anagnostopoulos I, Hummel M, Bornfeld N, Stein H (1998) Expression patterns of cyclin D1 and related proteins regulating G1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol 82:961\u2013970","journal-title":"Br J Ophthalmol"},{"key":"1914_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/his.12520","volume":"66","author":"P Ramani","year":"2015","unstructured":"Ramani P, Nash R, Rogers CA (2015) Aurora kinase A is superior to Ki67 as a prognostic indicator of survival in neuroblastoma. Histopathology 66:370\u2013379. \n                    https:\/\/doi.org\/10.1111\/his.12520","journal-title":"Histopathology"},{"key":"1914_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2147\/DDDT.S74127","volume":"9","author":"CX Yuan","year":"2015","unstructured":"Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ, Zhou SF (2015) Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther 9:487\u2013508. \n                    https:\/\/doi.org\/10.2147\/DDDT.S74127","journal-title":"Drug Des Devel Ther"},{"key":"1914_CR26","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/S0090-4295(03)00236-X","volume":"61","author":"SF Shariat","year":"2003","unstructured":"Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP (2003) Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61:1140\u20131145","journal-title":"Urology"},{"key":"1914_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1369\/jhc.2008.952044","volume":"57","author":"A Bressenot","year":"2009","unstructured":"Bressenot A, Marchal S, Bezdetnaya L, Garrier J, Guillemin F, Plenat F (2009) Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma. J Histochem Cytochem 57:289\u2013300. \n                    https:\/\/doi.org\/10.1369\/jhc.2008.952044","journal-title":"J Histochem Cytochem"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-018-1914-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-1914-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-1914-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T14:43:49Z","timestamp":1568904229000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-018-1914-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1914"],"URL":"https:\/\/doi.org\/10.1007\/s11255-018-1914-x","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"6 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}